A number of research firms have changed their ratings and price targets for BioMarin Pharmaceutical (NASDAQ: BMRN):
- 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Scotiabank from $95.00 to $78.00. They now have a “sector perform” rating on the stock.
- 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Royal Bank of Canada from $100.00 to $85.00. They now have a “sector perform” rating on the stock.
- 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Wells Fargo & Company from $115.00 to $90.00. They now have an “overweight” rating on the stock.
- 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Sanford C. Bernstein from $116.00 to $90.00. They now have an “outperform” rating on the stock.
- 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Truist Financial Co. from $118.00 to $90.00. They now have a “buy” rating on the stock.
- 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Stifel Nicolaus from $115.00 to $87.00. They now have a “buy” rating on the stock.
- 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Bank of America Co. from $130.00 to $115.00. They now have a “buy” rating on the stock.
- 9/13/2024 – BioMarin Pharmaceutical had its “hold” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $93.00 price target on the stock.
- 9/9/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
- 9/5/2024 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $100.00 price target on the stock.
- 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Scotiabank from $86.00 to $95.00. They now have a “sector perform” rating on the stock.
- 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at JPMorgan Chase & Co. from $111.00 to $120.00. They now have an “overweight” rating on the stock.
- 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Piper Sandler from $107.00 to $122.00. They now have an “overweight” rating on the stock.
- 9/5/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Truist Financial Co. from $140.00 to $118.00. They now have a “buy” rating on the stock.
- 8/30/2024 – BioMarin Pharmaceutical was upgraded by analysts at William Blair to a “strong-buy” rating.
- 8/27/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $107.00 price target on the stock.
- 8/21/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Stifel Nicolaus from $112.00 to $115.00. They now have a “buy” rating on the stock.
- 8/20/2024 – BioMarin Pharmaceutical was upgraded by analysts at Sanford C. Bernstein from a “market perform” rating to an “outperform” rating. They now have a $110.00 price target on the stock, up previously from $94.00.
- 8/8/2024 – BioMarin Pharmaceutical was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Scotiabank from $85.00 to $86.00. They now have a “sector perform” rating on the stock.
- 8/6/2024 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $100.00 price target on the stock.
- 8/6/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Barclays PLC from $111.00 to $110.00. They now have an “overweight” rating on the stock.
- 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Evercore ISI from $113.00 to $115.00. They now have an “outperform” rating on the stock.
- 8/6/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at TD Cowen from $125.00 to $120.00. They now have a “buy” rating on the stock.
- 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Stifel Nicolaus from $108.00 to $112.00. They now have a “buy” rating on the stock.
- 8/5/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
BioMarin Pharmaceutical Trading Down 0.6 %
BMRN opened at $69.66 on Thursday. The stock has a market capitalization of $13.23 billion, a PE ratio of 65.10, a P/E/G ratio of 0.80 and a beta of 0.32. BioMarin Pharmaceutical Inc. has a one year low of $67.75 and a one year high of $99.56. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.95 and a current ratio of 3.05. The business’s 50 day moving average price is $83.20 and its 200 day moving average price is $83.40.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.39. The business had revenue of $712.03 million during the quarter, compared to analysts’ expectations of $660.51 million. BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. As a group, equities research analysts expect that BioMarin Pharmaceutical Inc. will post 2.39 EPS for the current year.
Hedge Funds Weigh In On BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Stories
- Five stocks we like better than BioMarin Pharmaceutical
- Consumer Discretionary Stocks Explained
- SCHD ETF: Unlocking Passive Income With Strong Returns
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- NuScale Power Soars 270% – Analysts Forecasts More Gains Ahead
- Roth IRA Calculator: Calculate Your Potential Returns
- Harness the Power of Dividend ETFs for Steady Income Growth
Receive News & Ratings for BioMarin Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.